SCHEMBL1663628

SCHEMBL1663628

O=c1c2ccc(O)cc2nc(N2CCCC2)n1-c1ccc(Cl)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.72
ALDH1A1 P00352 2/20 0.72
MEN1 O00255 1/20 0.72
CYP1A2 P05177 1/20 0.72
CYP3A4 P08684 1/20 0.72
GAA P10253 1/20 0.72
CYP2D6 P10635 1/20 0.72
CYP2C9 P11712 1/20 0.72
HPGD P15428 1/20 0.72
TSHR P16473 1/20 0.72
MAPK1 P28482 1/20 0.72
CYP2C19 P33261 1/20 0.72
KMT2A Q03164 1/20 0.72
NPSR1 Q6W5P4 1/20 0.72
HSD17B10 Q99714 1/20 0.72
SMN1; SMN2 Q16637 3/20 0.53
ESR1 P03372 2/20 0.51
TRPV4 Q9HBA0 3/20 0.47
TRPV1 Q8NER1 1/20 0.43
EGFR P00533 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663502 0.90 ALDH1A1 (0.58) KDM4EALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL1663630 0.78 ESR1 (0.57) KDM4EALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL10446285 0.77 ESR1 (0.50) KDM4EALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL1664004 0.77 ESR1 (0.84) KDM4EALDH1A1MEN1GAAKMT2A
SCHEMBL10446279 0.77 ESR1 (0.52) KDM4EALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL1663648 0.75 ESR1 (0.53) KDM4EALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL1664336 0.75 ESR1 (0.60) ALDH1A1TSHRMAPK1NPSR1SMN1; SMN2
SCHEMBL1663398 0.75 TRPV1 (0.72) KDM4EALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL1665830 0.74 TRPV1 (0.61) KDM4EALDH1A1MEN1CYP1A2CYP3A4
SCHEMBL1665665 0.74 ESR1 (0.52) KDM4EALDH1A1MEN1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 KDM4E 2742/4885ALDH1A1 2499/4885MEN1 4252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.